Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.
暂无分享,去创建一个
B. Barlogie | M. Dimopoulos | P. Sonneveld | R. Fonseca | M. Boccadoro | V. Bolejack | H. Kantarjian | G. Garcia-Manero | S. Verstovsek | E. Jabbour | S. O'brien | P. Greipp | J. S. San Miguel | H. Ludwig | W. Wierda | J. Harousseau | I. Turesson | B. Durie | J. Bladé | K. Shimizu | C. Shustik | J. Crowley | A. Palumbo | M. Attal | S. Faderl | D. Joshua | M. Cavo | Dan Jones | M. Rios | Jordi Cortés | J. Westin | R. Kyle | M. Beksaç | Jenny Shan | Neeli Reddy